Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Powerverse and Teltonika Energy Partner to Unlock Intelligent Home Energy & Flexibility19.3.2026 08:00:00 CET | Press release
LONDON, UK / ACCESS Newswire / March 19, 2026 / Powerverse has partnered with Teltonika Energy, part of the Teltonika group, a multinational leader in IoT innovation, to deliver an AI-driven home energy ecosystem that enhances user experience, unlocks flexibility services and drives long-term customer value. Teltonika Energy's hardware is built with reliability, connectivity and performance at its core, and its devices are designed to support the next generation of intelligent home energy systems. "Teltonika Energy is globally recognised for its high-quality, IoT-engineered hardware," said Richard Britton, CEO of Powerverse. "We are thrilled to combine their robust devices with our AI-driven platform to help customers move beyond simple smart control and into active market participation. Together, we are delivering a fully integrated, end-to-end solution that makes it effortless for users to lower costs, reduce their carbon footprint, and unlock the full long-term value of home energy
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of Care.com from IAC18.3.2026 23:45:00 CET | Press release
LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has completed the acquisition of Care.com from IAC Inc. (NASDAQ: IAC). Care.com is a leading platform and brand in the growing $400 billion market for family care, anchored by the largest online network of background-checked child and senior caregivers in the U.S. Care.com operates both a scaled consumer marketplace and an enterprise benefits platform. Since 2007, more than 45 million people have turned to Care.com to find child care, senior care, pet care and housekeeping support. Care.com also partners with more than 700 employers, including many of the Fortune 100, to deliver care-related benefits that combine access to the Care.com platform and comprehensive backup care solutions provided in-home,
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution17.3.2026 15:05:00 CET | Press release
Redshift for Vectorworks now available, Autodesk Revit® beta open for sign-ups, and Graphisoft Archicad releasing later in 2026. Maxon unveils a deeper look at its end-to-end 3D workflow for architects and designers in 2026 and beyond. BAD HOMBURG, DE / ACCESS Newswire / March 17, 2026 / Maxon, maker of powerful, approachable software solutions for creators working in 2D and 3D design, motion graphics, visual effects, gaming, and more, today announced the commercial availability of Redshift for Vectorworks. Additionally, the company announced the beta launch of Redshift for Autodesk Revit®. This marks the next major milestone in Maxon's expansion into the Architecture, Engineering & Construction (AEC) market, with additional integrations planned. Engineered for architects and interior designers, Maxon's AEC solution brings the company's industry-proven cinematic rendering technology, Redshift, and the creative depth of Cinema 4D directly into professional archviz workflows. Designed as
Sauce Labs CEO, Prince Kohli, Says $1 Trillion Software Quality Industry Has Been "Building Wrong" for 20 Years17.3.2026 15:00:00 CET | Press release
The new Sauce AI for Test Authoring launch targets the most labor-intensive slice of the 22% of IT budgets spent on quality assurance, by shifting engineering teams from writing test cases to specifying business intent that the platform autonomously turns into self-improving test suites. SAN FRANCISCO, CA / ACCESS Newswire / March 17, 2026 / Sauce Labs Inc., the world's largest full-lifecycle, test automation platform, today announced the general availability of Sauce AI for Test Authoring, an AI Agent that translates business intent into framework-agnostic executable test suites that can be run instantly on Sauce Labs' virtual and real-device clouds. This launch introduces a new paradigm for DevOps: Intent-Driven Testing, designed to bridge the "Velocity and Quality Gap", the widening distance between how fast AI generates code and how slowly teams can validate it for enterprise-grade quality. High-quality test creation is one of software development's most persistent bottlenecks. Dev
Datavault AI Schedules Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 202617.3.2026 12:00:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / March 17, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, today announced that it will report financial results for its fourth quarter and full year 2025 prior to market open on Thursday, March 19, 2026. Following the release, Datavault AI will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET. Conference Call and Webcast Information Date: Thursday, March 19, 2026, at 8:30 a.m. ET Participant Dial-in (US): 1-877-405-1216 Participant Dial-in (International): 1-201-689-8336 Webcast Access: Click Here Datavault AI CEO, Nathaniel Bradley, and CFO Brett Moyer, will be presenting. A replay of the webcast will be made available later in the day in the Investors/Presentations section of the Datavault AI website: Click Here. About Datavault AI Inc. Datavault AI TM (NASDAQ:DVLT) is leading the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom